{"id":"meloxicam-nanocrystal-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal bleeding or ulceration"},{"rate":null,"effect":"Dyspepsia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Cardiovascular events (myocardial infarction, stroke)"},{"rate":null,"effect":"Renal impairment"},{"rate":null,"effect":"Hypertension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Meloxicam selectively inhibits COX-2 and COX-1 enzymes, which are responsible for producing prostaglandins that mediate inflammation, pain, and fever. The nanocrystal formulation enhances bioavailability and allows for parenteral (injection) administration, providing faster onset of action compared to oral formulations. This mechanism makes it effective for treating inflammatory and pain conditions.","oneSentence":"Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:36.136Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute pain management"},{"name":"Rheumatoid arthritis"},{"name":"Osteoarthritis"},{"name":"Ankylosing spondylitis"}]},"trialDetails":[{"nctId":"NCT06902090","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Meloxicam Nanocrystal Injection in Healthy Subjects","status":"COMPLETED","sponsor":"Yangtze River Pharmaceutical Group Co., Ltd.","startDate":"2023-07-05","conditions":"Pain","enrollment":20},{"nctId":"NCT06379165","phase":"PHASE3","title":"Efficacy and Safety Study of Meloxicam Nanocrystal Injection for the Treatment of Moderate to Severe Pain","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2023-05-17","conditions":"Pain","enrollment":192}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Meloxicam Nanocrystal Injection","genericName":"Meloxicam Nanocrystal Injection","companyName":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","companyId":"cspc-zhongqi-pharmaceutical-technology-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Meloxicam Nanocrystal Injection is a small molecule that acts as a cyclooxygenase-2 inhibitor, targeting Prostaglandin G/H synthase 2. It is being studied for the treatment of moderate to severe pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}